Skip to main content
S. 5002 117th Congress Senate

FDA Modernization Act 2.0

Official title: A bill to allow for alternatives to animal testing for purposes of drug and biological product applications.

Introduced: September 29, 2022 Introduced by: Rand Paul Republican · Kentucky See on congress.gov
Health Animal protection and human-animal relationshipsDrug safety, medical device, and laboratory regulationMedical researchPrescription drugsResearch and development
Sign in to write a letter Sign in to watch
This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 6 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Sep 29, 2022
Held at the desk.
Sep 29, 2022
Message on Senate action sent to the House.
Sep 29, 2022
Received in the House.
Sep 29, 2022
Introduced in the Senate, read twice, considered, read the third time, and passed without amendment by Unanimous Consent. (consideration: CR S5514-5515; text: CR S5514-5515)
Sep 29, 2022
Passed/agreed to in Senate: Introduced in the Senate, read twice, considered, read the third time, and passed without amendment by Unanimous Consent.
Sep 29, 2022
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action September 29, 2022

Held at the desk.

 Plain-English summary Congressional Research Service

FDA Modernization Act 2.0

This bill authorizes the use of certain alternatives to animal testing, including cell-based assays and computer models, to obtain an exemption from the Food and Drug Administration to investigate the safety and effectiveness of a drug.

The bill also removes a requirement to use animal studies as part of the process to obtain a license for a biological product that is biosimilar or interchangeable with another biological product.

 Related & companion bills 2
  • S 4348 FDASLA Act of 2022
  • S 4288 Reducing Animal Testing Act
 Bill text 2 versions

Source documents hosted by congress.gov.

 Cosponsors 10
All 10 Democratic 3 Republican 5 Independent 2
D
Booker, Cory A.
New Jersey · Sep 29, 2022
 R
Collins, Susan M.
Maine · Sep 29, 2022
 R
Crapo, Mike
Idaho · Sep 29, 2022
 I
King, Angus S., Jr.
Maine · Sep 29, 2022
 D
Luján, Ben Ray
New Mexico · Sep 29, 2022
 R
Marshall, Roger
Kansas · Sep 29, 2022
 D
Padilla, Alex
California · Sep 29, 2022
 I
Sanders, Bernard
Vermont · Sep 29, 2022
 R
Scott, Rick
Florida · Sep 29, 2022
 R
Tuberville, Tommy
Alabama · Sep 29, 2022
Cite this page click to expand
APA
U.S. Congress. (2026). S. 5002: FDA Modernization Act 2.0. 117th Congress. Open America. https://openamerica.io/bill/117-S-5002/
MLA
"S. 5002: FDA Modernization Act 2.0." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-S-5002/.
Bluebook (legal)
S. 5002, 117th Cong. (2026), https://openamerica.io/bill/117-S-5002/.
Markdown link
[S. 5002: FDA Modernization Act 2.0](https://openamerica.io/bill/117-S-5002/)
Report a problem